Lilly (Eli) has grown revenue 39% a year over three years and 24% a year over five, with earnings per share compounding at 61%. Revenue growth, 3-year annual rate: +39% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: +24%, growth has picked up over the last three years. Earnings per share, 3-year rate: +61%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 20, FY2006 to FY2025, as filed.

LLYLilly (Eli)

HealthcareUSD

$1,189.68

$621.2652 weeks$1.3K

Is it growing?

Is LLY growing?

Lilly (Eli) has grown revenue 39% a year over three years and 24% a year over five, with earnings per share compounding at 61%.

+39%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +24%
Revenue growth, 5-year rate · +39% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +61%
Earnings per share, 3-year rate · revenue +39% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 20
Years of annual history on file · FY2006 to FY2025, as filed